Who founded Invea Therapeutics, Inc.?

Invea Therapeutics, Inc. was founded by Krishnan Nandabalan in 2021.

Who are Invea Therapeutics, Inc.'s investors?

Invea Therapeutics, Inc.'s investors include Connecticut Innovations.

How much funding has Invea Therapeutics, Inc. raised?

Invea Therapeutics, Inc. has disclosed $1.9M raised across 3 rounds.

Where is Invea Therapeutics, Inc. headquartered?

Invea Therapeutics, Inc. is headquartered in Guilford, US.

Invea Therapeutics, Inc.

Guilford, US · Founded 2021 · Delaware corporation · 7 employees on LinkedIn · 1 known investors

Invea Therapeutics is a biotechnology company developing oral small molecule therapies for immune-mediated inflammatory diseases (IMIDs), using artificial intelligence and machine learning to study inflammation mechanisms such as mast cell and inflammasome biology. It targets both common and rare IMIDs to serve patients with chronic inflammatory conditions.

AI & Machine Learning Biotech Digital Health

Founders & leadership

Invea Therapeutics, Inc. was founded in 2021 by Krishnan Nandabalan.

Krishnan Nandabalan inFounder, Chairman, President, CEOCEO, Founder, & President, InveniAI at AIF

Salvatore AlesciinChief Scientific Officer

Aman KantinChief Operating Officer

Michael J. AielloChief Financial Officer

"Shunichiro ""Steve""" OkadaNamed on SEC filing

Sandeep LaumasNamed on SEC filing

Vimal MehtaNamed on SEC filing

Board

Demetrios KydonieusinBoard director

Kerrie BradyBoard director

Stephen DobersteinBoard director

Jonathan ZalevskyinBoard director

Investors · 1

Connecticut InnovationsNew Haven · $500K – $2M

Reported raises · per SEC filings

Form D private placements

$1.9M disclosed across 3 rounds · 2022–2025

▶$120.3KraisedDec 2025 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Demetrios KydonieusDirector
Aman KantExecutive Officer
Salvatore AlesciExecutive Officer
Michael J. AielloExecutive Officer
Jonathan ZalevskyDirector
"Shunichiro ""Steve""" OkadaExecutive Officer
Stephen DobersteinDirector
Kerrie BradyDirector
Krishnan NandabalanExecutive Officer, Director

Offering amount: $120.3K
Amount sold: $120.3K
Minimum investment: $10K
First sale: Oct 2025
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$300KraisedApr 2025 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Krishnan NandabalanExecutive Officer, Director
Salvatore AlesciExecutive Officer
Demetrios KydonieusDirector
Kerrie BradyDirector
Aman KantExecutive Officer
Stephen DobersteinDirector
Jonathan ZalevskyDirector
"Shunichiro ""Steve""" OkadaExecutive Officer
Michael J. AielloExecutive Officer

Offering amount: $600K
Amount sold: $300K
Minimum investment: $10K
First sale: Mar 2025
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.5MraisedApr 2022 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Salvatore AlesciExecutive Officer
Jonathan ZalevskyDirector
"Shunichiro ""Steve""" OkadaExecutive Officer
Aman KantExecutive Officer
Sandeep LaumasDirector
Demetrios KydonieusDirector
Vimal MehtaDirector
Michael AielloExecutive Officer
Krishnan NandabalanExecutive Officer, Director, Promoter
Kerrie BradyDirector

Offering amount: $5.8M
Amount sold: $1.5M
First sale: Apr 2022
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Enveda Biosciences12 shared keywordsEnveda operates a drug-discovery platform that analyzes natural samples—primarily plant-derived molecules—using mass spectrometry, AI foundation models, and automated high-throughput labs to identify their chemical structures and therapeutic properties. The company maintains a searchable library of plant molecules to find new medicines and applies its technology toward human and planetary health challenges.

IQVIA12 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.

Bioworld11 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Invea Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Invea Therapeutics, Inc. do?: Invea Therapeutics is a biotechnology company developing oral small molecule therapies for immune-mediated inflammatory diseases (IMIDs), using artificial intelligence and machine learning to study inflammation mechanisms such as mast cell and inflammasome biology. It targets both common and rare IMIDs to serve patients with chronic inflammatory conditions.
Who founded Invea Therapeutics, Inc.?: Invea Therapeutics, Inc. was founded by Krishnan Nandabalan in 2021.
Who are Invea Therapeutics, Inc.'s investors?: Invea Therapeutics, Inc.'s investors include Connecticut Innovations.
How much funding has Invea Therapeutics, Inc. raised?: Invea Therapeutics, Inc. has disclosed $1.9M raised across 3 rounds.
Where is Invea Therapeutics, Inc. headquartered?: Invea Therapeutics, Inc. is headquartered in Guilford, US.